Some risk factors for epithelial ovarian cancer are modifiable, according to a study published online Jan. 6 in the ...

The guideline authors used data from 61 studies to provide recommendations on the use of neoadjuvant chemotherapy in patients with newly diagnosed, stage III-IV epithelial ovarian, fallopian tube, or ...

To develop a machine learning (ML) algorithm to predict survival probabilities for patients with epithelial ovarian cancer (EOC).Data were obtained from the SEER database for women diagnosed with EOC ...

Traditionally, chemotherapy was given after surgery (primary cytoreductive surgery (PCRS) and adjuvant chemotherapy). However, chemotherapy can be used before surgery (neoadjuvant chemotherapy (NACT) ...

Ovarian cancer is the deadliest gynecologic malignancy globally and is increasing in incidence and mortality with currently ...

Artificial intelligence (AI) models, particularly artificial neural networks and machine learning, outperform traditional methods in predicting post–complete cytoreduction outcomes in patients ...

A single-arm Phase II trial of vintafolide (EC-FV-02) was subsequently conducted in patients with recurrent/persistent ovarian, fallopian tube and primary peritoneal cancer, as well as endometrial ...

Nuvectis is also advancing NXP900 for YES1/SRC-expressing solid tumors, with promising early data showing no dose-limiting ...

To provide updated guidance regarding neoadjuvant chemotherapy (NACT) and primary cytoreductive surgery (PCS) among patients with stage III-IV epithelial ovarian, fallopian tube, or primary peritoneal ...

First-line maintenance (1LM) niraparib significantly extends progression-free survival (rwPFS) and time to next treatment ...